COVID-19: A Centennial Pandemic from Origin to Clinical Trials

Ruddhida R Vidwans 1  und Manendra Babu Lankadasari 2
  • 1 Department of Microbiology, Jain University, Bangalore, India
  • 2 , Independent Researcher, Dr. No: 6/30, PedhaVeedi, Gudiwada, Andhra Pradesh, India

Abstract

In December 2019, an unexpected interaction of coronavirus with human’s occurred for the third time in history after Severe Acute Respiratory Syndrome (SARS) in 2002-2003 and Middle East Respiratory Syndrome (MERS) in 2012. Soon the virus was confirmed as SARS-CoV-2, and the severity of its transmission lead the World Health Organization to declare it as World Pandemic. Due to its highly contagious nature, new methods like social distancing, self-hygiene and quarantine were being adopted by many countries to halt the transmission. Due to the dearth in specific therapeutics and/or vaccines against Coronavirus Disease (COVID-19), a significant thrust in drugs and vaccine discovery was ratified by all the nations. The current review comprehensively details about the emergence and molecular pathogenesis with an interesting timeline which notes all the major events during this crisis. Given the potential general readers and health workers, the symptoms and diagnostic approaches were simplified. Emphasis was given to therapeutic approaches and clinical trials section to support the translational research and to cope up with the viral outbreak.

Falls das inline PDF nicht korrekt dargestellt ist, können Sie das PDF hier herunterladen.

  • 1. Abdelmageed MI, Abdelmoneim AH, Mustafa MI, Elfadol NM, Murshed NS, Shantier SW, Makhawi AM (2020) Design of multi epitope-based peptide vaccine against E protein of human 2019-nCoV: An immunoinformatics approach. BioRxiv 2020.02.04.934232. doi: 10.1101/2020.02.04.934232

  • 2. Agostini ML, Andres EL, Sims AC, Graham RL, Sheahan TP, Lu X, Smith EC, Case JB, Feng JY, Jordan R, Ray AS, Cihlar T, Siegel D, Mackman RL, Clarke MO, Baric RS, Denison MR (2018) Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. MBio 9:e00221-18. doi: 10.1128/mBio.00221-18

  • 3. Albarello F, Pianura E, Di SF, Cristofaro M, Petrone A, Marchioni L, Palazzolo C, Schininà V, Nicastri E, Petrosillo N, Campioni P, Eskild P, Zumla A, Ippolito G, Abbonizio MA, Agrati C, Amadei G, Amendola A, Antonini M, Barbaro R, Bartolini B, Benigni M, Bevilacqua N, Bordi L, Bordoni V, Branca M, Capobianchi MR, Caporale C, Caravella I, Carletti F, Castilletti C, Chiappini R, Ciaralli C, Colavita F, Corpolongo A, Curiale S, D’Abramo A, Dantimi C, Angelis AD, Angelis GD, Lorenzo RD, Stefano FD, Ferraro F, Fiorentini L, Frustaci A, Gallì P, Garotto G, Giancola ML, Giansante F, Giombini E, Greci MC, Lalle E, Lanini S, Lapa D, Lepore L, Lucia A, Lufrani F, Macchione M, Marani A, Mariano A, Marini MC, Maritti M, Matusali G, Meschi S, Montaldo FMC, Murachelli S, Noto R, Pallini E, Passeri V, Pelliccioni F, Petrecchia A, Pisciotta M, Pittalis S, Proietti C, Puro V, Rinonapoli G, Rueca M, Sacchi A, Sanasi F, Santagata C, Scarcia S, Scognamiglio P, Scorzolini L, Stazi G, Vaia F, Vairo F, Valli MB (2020) 2019-novel Coronavirus severe adult respiratory distress syndrome in two cases in Italy: An uncommon radiological presentation. Int J Infect Dis 93:192–197. doi: 10.1016/j.ijid.2020.02.043.

  • 4. Alraddadi BM, Watson JT, Almarashi A, Abedi GR, Turkistani A, Sadran M, Housa A, Almazro MA, Alraihan N, Banjar A, Albalawi E, Alhindi H, Choudhry AJ, Meiman JG, Paczkowski M, Curns A, Mounts A, Feikin DR, Marano N, Swerdlow DL, Gerber SI, Hajjeh R, Madani TA (2016) Risk factors for primary middle east respiratory syndrome coronavirus illness in humans, Saudi Arabia, 2014. Emerg Infect Dis 22:49–55. doi: 10.3201/eid2201.151340

  • 5. Aylward, Bruce (WHO), Liang W (PRC) (2020) Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19). In- The WHO-China Joint Mission on Coronavirus Disease 2019, 2019(February):16–24. https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf. Accessed 05 April 2020

  • 6. Boktor SW, Hafner JW (2020) Influenza. In: StatPearls. Treasure Island (FL). StatPearls Publishing. PMID: 29083802

  • 7. Casadevall A, Pirofski L (2020) The convalescent sera option for containing COVID-19. J Clin Invest 130:1545–1548. doi: 10.1172/jci138003

  • 8. Centers for Disease Control and Prevention (2020) CDC Laboratory Testing for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Serology Tests. http://www.cdc.gov/coronavirus/mers/lab/lab-testing.html. Accessed 05 April 2020

  • 9. Chen Y, Liu Q, Guo D (2020) Emerging coronaviruses: Genome structure, replication, and pathogenesis. J Med Virol 92:418–423. doi: 10.1002/jmv.25681

  • 10. Cheng Y, Wong R, Soo YOY, Wong WS, Lee CK, Ng MHL, Chan P, Wong KC, Leung CB, Cheng G (2005) Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis 24:44–46. doi: 10.1007/s10096-004-1271-9

  • 11. Cherry JD (2004) The chronology of the 2002-2003 SARS mini pandemic. Paediatr Respir Rev 5:262–269. doi: 10.1016/j.prrv.2004.07.009

  • 12. Chu CM, Cheng VCC, Hung IFN, Wong MML, Chan KH, Chan KS, Kao RYT, Poon LLM, Wong CLP, Guan Y, Peiris JS M, Yuen KY (2004) Role of lopinavir/ritonavir in the treatment of SARS: Initial virological and clinical findings. Thorax 59:252–256. doi: 10.1136/thorax.2003.012658

  • 13. Corman VM, Muth D, Niemeyer D, Drosten C (2018) Hosts and Sources of Endemic Human Coronaviruses. Adv Virus Res 100:163-188. doi: 10.1016/bs.aivir.2018.01.001

  • 14. Sobi (2020) Sobi ’ s Anakinra & Emapalumab Requested for Use in Targeted Clinical Study in Italy to Address Severe COVID-19 Cases. In: TrialSiteNews. https://www.trialsitenews.com/sobisanakinra-emapalumab-requested-for-usein-targeted-clinical-study-in-italy-to-address-severe-covid-19-cases/Accessed 05 April 2020.

  • 15. Cui J, Li F, Shi ZL (2019) Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol 17:181–192. doi: 10.1038/s41579-018-0118-9

  • 16. Jin Y, Yang H, Ji W, Wu W, Chen S, Zhang W, Duan G (2020) Virology, Epidemiology, Pathogenesis, and Control of COVID-19. Viruses 12:372. doi: 10.3390/v12040372

  • 17. Duan J, Yan X, Guo X, Cao W, Han W, Qi C, Feng J, Yang D, Gao G, Jin G (2005) A human SARS-CoV neutralizing antibody against epitope on S2 protein. Biochem Biophys Res Commun 333:186-193. doi: 10.1016/j.bbrc.2005.05.089

  • 18. Giamarellos-Bourboulis EJ, Netea MG, Rovina N, Akinosoglou K, Antoniadou A, Antonakos N, Damoraki G, Gkavogianni T, Adami ME, Katsaounou P, Ntaganou M (2020) Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure. Cell Host Microbe 27:992-1000.e3. doi: 10.1016/j.chom.2020.04.009

  • 19. Fan C, Li K, Ding Y, Lu WL, Wang J (2020) ACE2 Expression in Kidney and Testis May Cause Kidney and Testis Damage After 2019-nCoV Infection. MedRxiv 2020.02.12.20022418. doi: 10.1101/2020.02.12.20022418

  • 20. Fox RI (1993) Mechanism of action of hydroxychloroquine as an antirheumatic drug. Semin Arthritis Rheu 23:82–91. doi: 10.1016/S0049-0172(10)80012-5

  • 21. Furuta Y, Komeno T, Nakamura T (2017) Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc Jpn Acad, Ser B 93:449-463. https://doi.org/10.2183/pjab.93.027

  • 22. Ge XY, Li JL, Yang XL, Chmura AA, Zhu G, Epstein JH, Mazet JK, Hu B, Zhang W, Peng C, Zhang YJ, Luo CM, Tan B, Wang N, Zhu Y, Crameri G, Zhang SY, Wang L F, Daszak P, Shi ZL (2013) Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor. Nature 503:535–538. doi: 10.1038/nature12711

  • 23. Gorbalenya AE, Baker SC, Baric RS, de Groot RJ, Drosten C, Gulyaeva AA, Haagmans BL, Lauber C, Leontovich AM, Neuman BW, Penzar D, Perlman S, Poon LM, Samborskiy DV, Sidorov IA, Sola I, Ziebuhr J (2020) The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol 5:536–544. doi: 10.1038/s41564-020-0695-z

  • 24. Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, Feldt T, Green G, Green ML, Lescure FX, Nicastri E, Oda R, Yo K, Quiros RE, Studemeister A, Redinski J, Ahmed S, Bernett J, Chelliah D, Chen D, Chihara S, Cohen SH, Cunningham J, D’Arminio MA, Ismail S, Kato H, Lapadula G, L’Her E, Maeno T, Majumder S, Massari M, Mora RM, Mutoh Y, Nguyen D, Verweij E, Zoufaly A, Osinusi AO, DeZure A, Zhao Y, Zhong L, Chokkalingam A, Elboudwarej E, Telep L, Timbs L, Henne I, Sellers S, Cao H, Tan SK, Winterbourne L, Desai P, Mera R, Gaggar A, Myers RP, Brainard DM, Childs R, Flanigan T (2020) Compassionate Use of Remdesivir for Patients with Severe Covid-19. N Engl J Med 382:2327-2336. doi: 10.1056/NEJMoa2007016

  • 25. Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, Tan KS, Wang DY, Yan Y (2020) The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Military Med Res 7:11. doi: 10.1186/s40779-020-00240-0

  • 26. Gyawali B, Ramakrishna K, Dhamoon AS (2019) Sepsis: The evolution in definition, pathophysiology, and management. SAGE Open Med 7:1-13 doi: 10.1177/2050312119835043

  • 27. Hamming I, Timens W, Bulthuis MLC, Lely AT, Navis GJ, Van GH (2004) Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol 203:631–637. doi: 10.1002/path.1570

  • 28. Harrison C (2020) Coronavirus puts drug repurposing on the fast track. Nat Biotechnol 38:379–381. doi: 10.1038/d41587-020-00003-1

  • 29. Healy M (2020) How a discovery that brought us Viagra could help those battling the coronavirus. In: Bangor Daily News, LA. https://www.healthleadersmedia.com/innovation/how-discovery-brought-us-viagra-could-help-those-battling-coronavirus. Accessed 06 April 2020

  • 30. Hodgson J (2020) The pandemic pipeline. Nat Biotechnol 38:523-532. doi: 10.1038/d41587-020-00005-z

  • 31. Hoehl S, Rabenau H, Berger A, Kortenbusch M, Cinatl J, Bojkova D, Behrens P, Böddinghaus B, Götsch U, Naujoks F, Neumann P, Schork J, Tiarks-Jungk P, Walczok A, Eickmann M, Vehreschild M, Kann G, Wolf T, Gottschalk R, Ciesek S (2020) Evidence of SARS-CoV-2 Infection in Returning Travelers from Wuhan, China. N Engl J Med 382:1278–1280. doi: 10.1056/NEJMc2001899

  • 32. Hongyi C, Zhicheng Z, Li W, Zhihua H, Fanghua G, Xiaodong L, Yahong C, Jinzi JW (2020) First Clinical Study Using HCV Protease Inhibitor Danoprevir to Treat Naïve and Experienced COVID-19 Patients Hongyi. MedRxiv 2020.03.22.20034041. doi: 10.1101/2020.03.22.20034041

  • 33. Hotchkiss RS, Moldawer LL, Opal SM, Reinhart K, Turnbull IR, Vincent JL (2016) Sepsis and septic shock. Nat Rev Dis Primers 2:1-21. doi: 10.1038/nrdp.2016.45

  • 34. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395:497–506. doi: 10.1016/S0140-6736(20)30183-5

  • 35. Hussain S, Pan J, Chen Y, Yang Y, Xu J, Peng Y, Wu Y, Li Z, Zhu Y, Tien P, Guo D (2005) Identification of Novel Subgenomic RNAs and Noncanonical Transcription Initiation Signals of Severe Acute Respiratory Syndrome Coronavirus. J Virol 79:5288–5295. doi: 10.1128/jvi.79.9.5288-5295.2005

  • 36. Kim UJ, Won EJ, Kee SJ, Jung SI, Jang HC (2016) Combination therapy with lopinavir/ritonavir, ribavirin and interferona for Middle East respiratory syndrome. Antivir Ther 2:455–459. doi: 10.3851/IMP3002

  • 37. Lam TTY, Shum MHH, Zhu HC, Tong YG, Ni XB, Liao YS, Wei W, Cheung WYM, Li WJ, Li LF, Leung GM, Holmes EC, Hu YL, Guan Y (2020) Identifying SARS-CoV-2 related coronaviruses in Malayan pangolins. Nature. 1-4. doi: 10.1038/s41586-020-2169-0

  • 38. Lan J, Ge J, Yu J, Shan S, Zhou H, Fan S, Zhang Q, Shi X (2020) Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature 581:215-220. doi: 10.1038/s41586-020-2180-5

  • 39. Lankadasari MB, Aparna JS, Mohammed S, James S, Aoki K, Binu VS, Nair S, Harikumar KB (2018) Targeting S1PR1/STAT3 loop abrogates desmoplasia and chemosensitizes pancreatic cancer to gemcitabine. Theranostics 8:3824-3840. doi: 10.7150/thno.25308

  • 40. Lau SKP, Woo PCY, Li KSM, Huang Y, Tsoi HW, Wong BHL, Wong SSY, Leung SY, Chan KH, Yuen KY (2005) Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats. Proc Natl Acad Sci USA 102:14040–14045. doi: 10.1073/pnas.0506735102

  • 41. Liao J, Fan S, Chen J, Wu J, Xu S, Guo Y, Li C, Zhang X, Wu C, Mou H, Song C, Li F, Wu G, Zhang J, Guo L, Liu H, Lv J, Xu L, Lang C (2020) Epidemiological and clinical characteristics of COVID-19 in adolescents and young adults. MedRxiv 2020.03.10.20032136. doi: 10.1101/2020.03.10.20032136

  • 42. Lounder DT, Bin Q, De MC, Jordan MB (2019) Treatment of refractory hemophagocytic lymphohistiocytosis with emapalumab despite severe concurrent infections. Blood Adv 3:47–50. doi: 10.1182/bloodadvances.2018025858

  • 43. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, Wang W, Song H, Huang B, Zhu N, Bi Y, Ma X, Zhan F, Wang L, Hu T, Zhou H, Hu Z, Zhou W, Zhao L, Chen J, Meng Y, Wang J, Lin Y, Yuan J, Xie Z, Ma J, Liu WJ, Wang D, Xu W, Holmes EC, Gao GF, Wu G, Chen W, Shi W, Tan W (2020) Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 395:565–574. doi: 10.1016/S0140-6736(20)30251-8

  • 44. Lythgoe MP, Middleton P (2020) Ongoing Clinical Trials for the Management of the COVID-19 Pandemic. Trends in Pharmacological Sci 41:363-382. doi: 10.1016/j.tips.2020.03.006

  • 45. Madjid M, Lillibridge S, Mirhaji P, Casscells W (2020) Influenza as a bioweapon. J R Soc Med 96:345–346. doi: 10.1177/014107680309600709

  • 46. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ (2020) COVID-19: consider cytokine storm syndromes and immunosuppression. The Lancet 395:1033–1034. doi: 10.1016/S0140-6736(20)30628-0

  • 47. Mei X, Lee HC, Diao KY, Huang M, Lin B, Liu C, Xie Z, Ma Y, Robson PM, Chung M, Bernheim A, Mani V, Calcagno C, Li K, Li S, Shan H, Lv J, Zhao T, Xia J, Long Q, Steinberger S, Jacobi A, Deyer T, Luksza M, Liu F, Little BP, Fayad ZA, Yang Y (2020) Artificial intelligence-enabled rapid diagnosis of patients with COVID-19. Nat Med 1-5. doi: 10.1038/s41591-020-0931-3

  • 48. Mishra S, Carnahan R (2020) Coronavirus : A new type of vaccine using RNA could help defeat COVID-19. 2, 1–5, Australia. In: The Conversation Blog. https://theconversation.com/coronavirus-anew-type-of-vaccine-using-rna-could-help-defeat-covid-19-133217. Accessed 06 May 2020

  • 49. Morgenstern B, Michaelis M, Baer PC, Doerr HW, Cinatl J (2005) Ribavirin and interferon-β synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines. Biochem Bioph Res Co 326:905-908. doi: 10.1016/j.bbrc.2004.11.128

  • 50. Myhrvold C, Freije CA, Gootenberg JS, Abudayyeh OO, Metsky HC, Durbin AF, Kellner MJ, Tan AL, Paul LM, Parham LA, Garcia KF, Barnes KG, Chak B, Mondini A, Nogueira ML, Isern S, Michael SF, Lorenzana I, Yozwiak NL, MacInnis BL, Bosch I, Gehrke L, Zhang F, Sabeti PC (2018) Field-deployable viral diagnostics using CRISPR-Cas13. Science, 360:444–448. doi: 10.1126/science.aas8836

  • 51. Pan L, Mu M, Ren HG, Yang P (2020) Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China: a descriptive, cross-sectional, multicenter study. Am J Gastroenterol 115:766-773. doi: 10.14309/ajg.0000000000000620

  • 52. Perlman S, Netland J (2009) Coronaviruses post-SARS: Update on replication and pathogenesis. Nat Rev Microbiol 7:439–450. doi:10.1038/nrmicro2147

  • 53. Peroni JF, Borjesson DL (2011) Anti-Inflammatory and Immunomodulatory Activities of Stem Cells. Veterinary Clinics of North America - Equine Practice 27:351–362. doi: 10.1016/j.cveq.2011.06.003

  • 54. Su H, Yang M, Wan C, Yi L, Tang F, Zhu H, Yi F, Yang H, Fogo AB, Nie X, Zhang C (2020) Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China. Kidney Int 1-9. doi: 10.1016/j.kint.2020.04.003

  • 55. Tai W, He L, Zhang X, Pu J, Voronin D, Jiang S, Zhou Y, Du L (2020) Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine. Cell Mol Immunol 17:613–620. doi:10.1038/s41423-020-0400-4

  • 56. Tang X, Wu CLX, Song Y, Yao X, Wu X, Dung Y, Zhang H, Wang Y, Qian Z, Cui J, Lu J (2020b) On the origin and continuing evolution of SARS-CoV-2. Natl Sci Rev nwaa036. doi: 10.1093/nsr/nwaa036

  • 57. Tetro JA (2020) Is COVID-19 receiving ADE from other coronaviruses? Microbe Infect 22:72–73. doi: 10.1016/j.micinf.2020.02.006

  • 58. Triana-Baltzer GB, Gubareva LV, Nicholls JM, Pearce MB, Mishin VP, Belser JA, Chen LM, Chan RWY, Chan MCW, Hedlund M, Larson JL, Moss RB, Katz JM, Tumpey TM, Fang F (2009) Novel pandemic influenza A(H1N1) viruses are potently inhibited by DAS181, a sialidase fusion protein. PLoS ONE 4:12–14. doi: 10.1371/journal.pone.0007788

  • 59. Van DN, Bushmaker T, Morris DH, Holbrook MG, Gamble A, Williamson BN, Tamin A, Harcourt JL, Thornburg NJ, Gerber SI, Lloyd-Smith JO (2020) Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. N Engl J Med 382:1564-1567. doi: 10.1056/NEJMc2004973

  • 60. Vijaykrishna D, Smith GJD, Zhang JX, Peiris JSM, Chen H, Guan Y (2007) Evolutionary Insights into the Ecology of Coronaviruses. J Virol 81:4012–4020. doi: 10.1128/jvi.02605-06

  • 61. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X, Peng Z (2020) Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA 323:1061–1069. doi: 10.1001/jama.2020.1585

  • 62. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao G (2020) Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 30:269–271. doi: 10.1038/s41422-020-0282-0

  • 63. Wang W, Xu Y, Gao R, Lu R, Han K, Wu G, Tan W (2020) Detection of SARS-CoV-2 in Different Types of Clinical Specimens. JAMA 323:1843–1844. doi: 10.1001/jama.2020.3786

  • 64. Wenzel RP, Edmond MB (2003) Managing SARS amidst uncertainty. N Engl J Med 348:1947–1948. doi: 10.1056/NEJMp030072

  • 65. WHO (2020) Emergencies preparedness, response. Pneumonia of unknown origin – China. Disease outbreak news. In: WHO Website. https://www.who.int/csr/don/05-january-2020-pneumonia-of-unkown-cause-china/en/. Accessed 06 April 2020

  • 66. Wit ED, Doremalen NV, Falzarano D, Munster VJ (2016). REVIEWS SARS and MERS : recent insights into emerging coronaviruses. Nat Rev Microbiol 14:523–534. doi: 10.1038/nrmicro.2016.81

  • 67. Worldometer Corona (2020) COVID-19 CORONAVIRUS PANDEMIC. In: Worldometer Corona https://www.worldometers.info/coronaviru/ Accessed 09 June 2020

  • 68. Wu A, Peng Y, Huang B, Ding X, Wang X, Niu P, Meng J, Zhu Z, Zhang Z, Wang J, Sheng J, Quan L, Xia Z, Tan W, Cheng G, Jiang T (2020) Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China. Cell Host Microbe 27:325–328. doi: 10.1016/j.chom.2020.02.001

  • 69. Wu F, Zhao S, Yu B, Chen YM, Wang W, Hu Y, Song ZG, Tao ZW, Tian JH, Pei YY, Yuan ML, Zhang YL, Dai FH, Liu Y, Wang QM, Zheng JJ, Xu L, Holmes EC, Zhang YZ (2020) Complete genome characterisation of a novel coronavirus associated with severe human respiratory disease in Wuhan, China. BioRxiv 2020.01.24.919183. doi: 10.1101/2020.01.24.919183

  • 70. Wu Z, McGoogan JM (2020) Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases from the Chinese Center for Disease Control and Prevention. JAMA 323:1239-42. doi: 10.1001/jama.2020.2648

  • 71. Xia S, Zhu Y, Liu M, Lan Q, Xu W, Wu Y, Ying T, Liu S, Shi Z, Jiang S, Lu L (2020) Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein. Cell Mol Immunol 1-3. doi: 10.1038/s41423-020-0374-2

  • 72. Xiao F, Tang M, Zheng X, Liu Y, Li X, Shan H (2020) Evidence for Gastrointestinal Infection of SARS-CoV-2. Gastroenterology 158:1831-1833. doi: 10.1053/j.gastro.2020.02.055

  • 73. Xie L, Sun C, Luo C, Zhang Y, Zhang J, Yang J, Chen L, Yang J, Li J (2020) SARSCoV-2 and SARS-CoV Spike-RBD Structure and Receptor Binding Comparison and Potential Implications on Neutralizing Antibody and Vaccine Development. BioRxiv 2020.02.16.951723. doi: 10.1101/2020.02.16.951723

  • 74. Xiong C, Jiang L, Chen Y, Jiang Q (2020) Evolution and variation of 2019-novel coronavirus. BioRxiv 2020.01.30.926477. doi: org/10.1101/2020.01.30.926477

  • 75. Yamamoto N, Yang R, Yoshinaka Y, Amari S, Nakano T, Cinatl J, Rabenau H, Doerr HW, Hunsmann G, Otaka A, Tamamura H, Fujii N, Yamamoto N (2004) HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus. Biochem Bioph Res Co 318:719-25. doi: 10.1016/j.bbrc.2004.04.083

  • 76. Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, Zhao L, Dong E, Song C, Zhan S, Lu R, Li H, Liu D, Clinical D, Liu D, Tan W Liu D (2020) In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Main point : Hydroxychloroquine was found to be more potent than chloroquine at inhibiting SARS-CoV-2 in vit. Clin Infect Dis 2:1–25. doi: 10.1093/cid/ciaa237

  • 77. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, Si HR, Zhu Y, Li B, Huang CL, Chen HD, Chen J, Luo Y, Guo H, Jiang RD, Liu MQ, Chen Y, Shen XR, Wang X, Zheng XS, Zhao K, Chen QJ, Deng F, Liu LL, Yan B, Zhan FX, Wang YY, Xiao GF, Shi ZL (2020) A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579:270–273. doi: 10.1038/s41586-020-2012-7

  • 78. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P, Zhan F, Ma X, Wang D, Xu W, Wu G, Gao GF, Tan W (2020) A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 382:727–733. doi: 10.1056/NEJMoa2001017

OPEN ACCESS

Zeitschrift + Hefte

Suche